Study revealed the potential of Doxorubicin SLN in overcoming P-gp-mediated MDR both in-vitro in P388/ADR leukemia cells and in-vivo in murine leukemia mouse model (Ma et al., 2009). This evidence concerns the gene PGP and leukemia.